Lab21 gets license to Celera's CRS7
This article was originally published in Clinica
UK diagnostic testing services provider company Lab21 is set to offer Norwalk, Connecticut-based Celera's CRS7 test for cirrhosis risk in patients with chronic hepatitis C viral (HCV) infection through its sales networks in the UK and Ireland. The personalised CRS7 test, which Lab21 claims is the first clinical test that can predict the probability of a HCV patient progressing to liver fibrosis and cirrhosis, expands the company's presence in the UK and Irish markets for hepatology diagnostics tests. Financial details of the licensing agreement were not disclosed.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.